Enzo Biochem, Inc.  

(Public, NYSE:ENZ)   Watch this stock  
Find more results for ENZ
2.88
-0.12 (-4.00%)
Mar 27 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 2.85 - 3.03
52 week 2.51 - 6.13
Open 3.02
Vol / Avg. 0.00/312,798.00
Mkt cap 130.68M
P/E     -
Div/yield     -
EPS -0.26
Shares 45.37M
Beta 2.08
Inst. own 48%
Jun 8, 2015
Q3 2015 Enzo Biochem Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 13, 2015
Q2 2015 Enzo Biochem Inc Earnings Call
Mar 12, 2015
Q2 2015 Enzo Biochem Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Jan '15) 2014
Net profit margin -17.72% -10.40%
Operating margin -16.81% -10.61%
EBITD margin - -2.45%
Return on average assets -26.86% -16.17%
Return on average equity -46.24% -28.07%
Employees 433 -
CDP Score - -

Address

60 EXECUTIVE BLVD
FARMINGDALE, NY 11735
United States - Map
+1-516-7555500 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Enzo Biochem, Inc, (Enzo) is a life sciences and biotechnology company. The Company focuses on harnessing biological processes to develop research tools, diagnostics and therapeutics and provides esoteric and other test services to the medical community. The Company�s business is organized as three operating segments: Clinical Labs, Life Sciences and Therapeutics, of which the Therapeutics and Life Sciences segments have evolved out of the Company�s capabilities involving the use of nucleic acids as informational molecules and the use of compounds for immune modulation and augmented by the previous acquisitions of a number of related companies. The Clinical Labs division offers clinical diagnostic services. The Life Sciences division manufactures, develops and markets products and tools to life sciences, drug development and clinical research customers. The Therapeutics division develops treatment regimens for diseases and conditions for which current treatment options are ineffective.

Officers and directors

Barry W. Weiner President, Chief Financial Officer, Principal Accounting Officer, Treasurer, Director
Age: 63
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Elazar Rabbani Ph.D. Chairman of the Board, Chief Executive Officer, Secretary
Age: 70
Bio & Compensation  - Reuters
James O'Brien Senior Vice President - Finance
Bio & Compensation  - Reuters
Herbert B. Bass Vice President - Finance
Age: 64
Bio & Compensation  - Reuters
Paul C O'Brien Vice President - Global Human Resources
Age: 51
Bio & Compensation  - Reuters
David C. Goldberg Vice President - Corporate Development; Interim General Manager of Enzo Clinical Labs
Age: 56
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Bernard L. Kasten Jr., M.D. Lead Independent Director
Age: 67
Bio & Compensation  - Reuters
Gregory M. Bortz Independent Director
Age: 44
Bio & Compensation  - Reuters
Dov Perlysky Independent Director
Age: 52
Bio & Compensation  - Reuters